Detail
| LncRNA Name | H19 |
| Synonyms | H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2 |
| Region | GRCh38_11:1995176-2001470 Sequence |
| Ensembl | ENSG00000130600 |
| RefSeq | NR_002196 |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✘ |
| MiRNA | ✔ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR, Western blot, RIP, Luciferase reporter assay etc. |
| Sample | CRC tissues, cell lines (SW620, HCT-116) |
| Expression Pattern | up-regulated |
| Function Description | We showed that overexpression of H19/miR-675 enhanced the aggressive phenotype of breast cancer cells including increased cell proliferation and migration in vitro, and increased tumor growth and metastasis in vivo. Moreover, we identified ubiquitin ligase E3 family (c-Cbl and Cbl-b) as direct targets of miR-675 in breast cancer cells. Using a luciferase assay, we demonstrated that H19, through its microRNA, decreased both c-Cbl and Cbl-b expression in all breast cancer cell lines tested. |
| Pubmed ID | 26068968 |
| Year | 2015 |
| Title | The LncRNA H19 promotes epithelial to mesenchymal transition by functioning as MiRNA sponges in colorectal cancer. |
| External Links |
| Links for H19 | GenBank HGNC lncrnadb Noncode |
| Links for colorectal cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.